BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30007243)

  • 21. Corrigendum to"An insight into the medicinal perspective of synthetic analogs of indole: A review" [Eur. J. Med. Chem. 180 (2019) 562-612 11516].
    Thanikachalam PV; Maurya RK; Garg V; Monga V
    Eur J Med Chem; 2019 Dec; 183():111680. PubMed ID: 31520927
    [No Abstract]   [Full Text] [Related]  

  • 22. Corrigendum to "Discovery of orally active anticancer candidate CFI-400945 derived from biologically promising spirooxindoles: Success and challenges" [Eur. J. Med. Chem. 95 (2015) 35-40].
    Yu B; Yu Z; Qi PP; Yu DQ; Liu HM
    Eur J Med Chem; 2016 Nov; 124():248. PubMed ID: 27592393
    [No Abstract]   [Full Text] [Related]  

  • 23. Corrigendum to 'Synthesis and discovery of a drug candidate for treatment of idiopathic pulmonary fibrosis through inhibition of TGF-b1 pathway' [Eur. J. Med. Chem. 157 (2018) 229-247].
    Li X; Lu C; Liu S; Liu S; Su C; Xiao T; Bi Z; Sheng P; Huang M; Liu X; Wei Y; Zhao L; Miao S; Mao J; Huang K; Gao S; Liu N; Qi M; Liu T; Qin S; Wei L; Sun T; Ning W; Yang G; Zhou H; Yang C
    Eur J Med Chem; 2019 Feb; 163():403. PubMed ID: 30530191
    [No Abstract]   [Full Text] [Related]  

  • 24. Corrigendum to "Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview" [Eur. J. Med. Chem. 194 (2020) 112260].
    Mondal S; Adhikari N; Banerjee S; Amin SA; Jha T
    Eur J Med Chem; 2020 Nov; 205():112642. PubMed ID: 32750565
    [No Abstract]   [Full Text] [Related]  

  • 25. Corrigendum to "Pyridine and nitro-phenyl linked 1,3,4-thiadiazoles as MDR-TB inhibitors" [Eur. J. Med. Chem. 167 (2019) 1-9].
    Patel H; Jadhav H; Ansari I; Pawara R; Surana S
    Eur J Med Chem; 2020 Aug; 200():112413. PubMed ID: 32512481
    [No Abstract]   [Full Text] [Related]  

  • 26. Corrigendum to "Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer" [Eur. J. Med. Chem. 163 (2019) 787-803].
    Wang C; Wang B; Hou S; Xue L; Kang Z; Du J; Li Y; Liu X; Wang Q; Zhang C
    Eur J Med Chem; 2020 Jan; 186():111907. PubMed ID: 31791642
    [No Abstract]   [Full Text] [Related]  

  • 27. Corrigendum to "Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors" [Eur. J. Med. Chem. 180 (2019) 171e190].
    Liu R; Zhang Z; Yang H; Zhou K; Geng M; Zhou W; Zhang M; Huang X; Li Y
    Eur J Med Chem; 2020 Jan; 186():111899. PubMed ID: 31787358
    [No Abstract]   [Full Text] [Related]  

  • 28. Corrigendum to "New desulfured troglitazone derivatives: Improved synthesis and biological evaluation" [Eur. J. Med. Chem. 187 (2020) 111939].
    Dupommier D; Muller C; Comoy C; Mazerbourg S; Bordessa A; Piquard E; Pawlak M; Piquard F; Martin H; De Fays E; Grandemange S; Flament S; Boisbrun M
    Eur J Med Chem; 2020 Dec; 208():112834. PubMed ID: 32966897
    [No Abstract]   [Full Text] [Related]  

  • 29. Corrigendum to "Synthesis of the pH-sensitive nanoparticles based on the acylhydrazone bonds conjugated doxorubicin and studies on their in vivo anti-tumor effects" [Eur. J. Med. Chem. 260 (2023) 115715].
    Shi Y; Pan X; Xu S; Zhu H; Zhao B; Sun Z; Dong R; Li N; Hou X; Yang X
    Eur J Med Chem; 2023 Dec; 262():115887. PubMed ID: 37867086
    [No Abstract]   [Full Text] [Related]  

  • 30. Corrigendum to: Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib [Eur. J. Med. Chem. 172 (2019) 143-153].
    Poratti M; Marzaro G
    Eur J Med Chem; 2020 Jun; 195():112272. PubMed ID: 32251743
    [No Abstract]   [Full Text] [Related]  

  • 31. Corrigendum to "Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity" [Eur. J. Med. Chem. 122 (2016) 232-246].
    Gaura R; Pathania AS; Malik FA; Bhakuni RS; Verma RK
    Eur J Med Chem; 2022 May; 235():114277. PubMed ID: 35344906
    [No Abstract]   [Full Text] [Related]  

  • 32. Corrigendum to "1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma" [Eur. J. Med. Chem. 140 (2017) 84-91].
    Liu YM; HuangFu WC; Huang HL; Wu WC; Chen YL; Yen Y; Huang HL; Nien CY; Lai MJ; Pan SL; Liou JP
    Eur J Med Chem; 2020 Sep; 202():112633. PubMed ID: 32688164
    [No Abstract]   [Full Text] [Related]  

  • 33. Corrigendum to <'Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d] pyrimidine analogues as novel CHK1 inhibitors' [Eur. J. Med. Chem. 151 (2018) 836-848].
    Tian C; Han Z; Li Y; Wang M; Yang J; Wang X; Zhang Z; Liu J
    Eur J Med Chem; 2019 Jul; 173():184. PubMed ID: 31003059
    [No Abstract]   [Full Text] [Related]  

  • 34. Corrigendum to <' Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors' [Eur. J. Med. Chem. 211 (2021), 113109].
    Alvarez RM; García AB; Riesco-Fagundo C; Martín JI; Varela C; Rodríguez Hergueta A; González Cantalapiedra E; Oyarzabal J; Di Geronimo B; Lorenzo M; Albarrán MI; Cebriá A; Cebrián D; Martínez-González S; Blanco-Aparicio C; Pastor J
    Eur J Med Chem; 2021 Nov; 224():113703. PubMed ID: 34284231
    [No Abstract]   [Full Text] [Related]  

  • 35. Corrigendum to "Synthesis and evaluation of isoprenylation-resveratrol dimer derivatives against Alzheimer's disease" [Eur. J. Med. Chem. 163 (2019), 307-319. DOI: 10.1016/j.ejmech.2018.11.040].
    Tang YW; Shi CJ; Yang HL; Cai P; Liu QH; Yang XL; Kong LY; Wang XB
    Eur J Med Chem; 2024 Jun; ():116591. PubMed ID: 38890013
    [No Abstract]   [Full Text] [Related]  

  • 36. Corrigendum to "Search for new multi-target compounds against Alzheimer's disease among histamine H
    Bajda M; Łażewska D; Godyń J; Zaręba P; Kuder K; Hagenow S; Łątka K; Stawarska E; Stark H; Kieć-Kononowicz K; Malawska B
    Eur J Med Chem; 2020 Nov; 205():112611. PubMed ID: 32791398
    [No Abstract]   [Full Text] [Related]  

  • 37. Corrigendum to "A fluorine scan on the Zn
    Zhang B; Liu J; Gao D; Yu X; Wang J; Lei X
    Eur J Med Chem; 2020 Jul; 198():112340. PubMed ID: 32371332
    [No Abstract]   [Full Text] [Related]  

  • 38. Corrigendum to "N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression"[Eur. J. Med. Chem. 2020 Jan 1;185:111725].
    Mehndiratta S; Lin MH; Wu YW; Chen CH; Wu TY; Chuang KH; Chao MW; Chen YY; Pan SL; Chen MC; Liou JP
    Eur J Med Chem; 2020 Aug; 199():112406. PubMed ID: 32408215
    [No Abstract]   [Full Text] [Related]  

  • 39. Corrigendum to "Design, synthesis and evaluation of novel thienopyrimidine-based agents bearing diaryl urea functionality as potential inhibitors of angiogenesis" [Eur. J. Med. Chem 209 (2021) 112942].
    Faraji A; Oghabi Bakhshaiesh T; Hasanvand Z; Motahari R; Nazeri E; Boshagh MA; Firoozpour L; Mehrabi H; Khalaj A; Esmaeili R; Foroumadi A
    Eur J Med Chem; 2021 Mar; 214():113228. PubMed ID: 33550180
    [No Abstract]   [Full Text] [Related]  

  • 40. Corrigendum to "Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response" [Eur J Med Chem. 192 2020 112158].
    Wu WC; Liu YM; Lin MH; Liao YH; Lai MJ; Chuang HY; Hung TY; Chen CH; Liou JP
    Eur J Med Chem; 2020 Jun; 196():112329. PubMed ID: 32311605
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.